Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

NCT04614103 is registered in ClinicalTrials.gov with Iovance Biotherapeutics, Inc. as lead sponsor.

NCT NCT04614103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04614103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
Lead sponsor
Iovance Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 7, 2021
Completion date
December 31, 2031
Enrollment
170 (estimated)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non small cell lung cancer